BioSpace News Archive

As a company dedicated to expediting research related to the treatment and prevention of Alzheimer’s Disease, Cognitive Clinical Trials (CCT) is fundamentally changing the way these types of studies are performed.

Starting today, California doctors will have to check a patient’s prescription history before prescribing addictive opioids and other controlled substances. The legislation is the culmination of a years-long fight by families impacted by opioid abuse to mandate doctors consult a state prescription database in order to reduce opioid overprescribing and save lives.

The Georgia Power Foundation recently completed a three-year investment of $1 million to Children’s Healthcare of Atlanta’s newly-opened Advanced Pediatrics Center. The Georgia Power Foundation is a non-profit 501(c)(3) organization and the third-largest corporate giving foundation in Georgia.

Novanta Inc. (Nasdaq: NOVT) (the “Company”, “we”, “our”, “Novanta”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has acquired the remaining approximately 24 percent of the outstanding shares of Laser Quantum for an aggregate consideration of $45.7 million in cash and restricted stock.

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the Chardan 2nd Annual Genetic Medicines Conference on Tuesday, October 9, 2018 at 4:15 p.m. ET at the Westin Grand Central, New York.

Akebia Therapeutics, Inc. granted six newly-hired employees options to purchase an aggregate of 32,750 shares of Akebia’s common stock on September 28, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that ONPATTRO (patisiran) is now available in Germany.

Financing provides support for NDA filing of KPI-121 0.25%, INVELTYS launch, and topline results for the STRIDE-3 trial of KPI-121 0.25%

Kala Pharmaceuticals, Inc. announced today that it has commenced an underwritten public offering of 7,500,000 shares of its common stock.

the UK’s national centre for commercialisation of synthetic biology, is pleased to announce the launch of a new five-year strategy underpinned by a new £5M grant from UKRI and other sources.